Async vs. Synchronous Telehealth: Why Most GLP-1 Platforms Skip the Video Call

Watch a commercial for any GLP-1 telehealth platform and you'll see a video call. A smiling patient, a smiling clinician, a laptop. It's the image the industry wants in your head.

Now count how many of the top twenty telehealth platforms actually require a video call before prescribing. The answer is a handful. The rest of the industry runs on asynchronous care — you fill out a form, someone reviews it hours later, a prescription is written. No video. No conversation. No face.

Async isn't illegal. In most states, for non-controlled prescriptions, it isn't even unusual. But it's a real clinical trade-off hidden behind a marketing image. Here's how it works and when it matters.

What "asynchronous" actually means

In telehealth language, synchronous care happens in real time — video or phone call where you and the clinician talk. Asynchronous care is "store and forward" — you submit information (a form, photos, a self-recorded video, lab results) and a clinician reviews it later on their own schedule, often hours or days after you submit.

Most GLP-1 telehealth runs async because it's dramatically cheaper to operate. A single nurse practitioner can review 80–120 asynchronous intakes in a shift versus maybe 15–20 live video visits. That cost structure is what makes $199/month compounded GLP-1 plans possible.

The legal basis

The federal framework is the DEA's telemedicine rules, the HHS OIG guidance, and state medical board policies. Under the DEA's telemedicine flexibilities (extended several times since the COVID-era expansion), clinicians can prescribe most non-controlled medications via telehealth — including via async-only visits — provided state law allows it.

Semaglutide and tirzepatide are not controlled substances. Almost every state permits async visits for non-controlled prescriptions with a valid clinician-patient relationship. The "relationship" can be established through the intake form itself in most jurisdictions. This is the legal seam the entire compounded GLP-1 industry operates through.

The five ways async can fail a patient

1. The questionnaire misses something. A checkbox for "family history of thyroid cancer" isn't the same as a clinician asking, noticing a hesitation, and following up. Medullary thyroid carcinoma is a contraindication for both semaglutide and tirzepatide. In a video visit, a careful clinician asks twice.
2. Self-reported weight is wrong. BMI eligibility depends on accurate weight. Async platforms almost never verify it. Some do, via a "weigh-in on camera" photo — and those platforms are the ones worth paying more for.
3. Medication interactions go uncaught. GLP-1s slow gastric emptying, which alters the absorption of oral medications (birth control, thyroid hormone, antiepileptics). A form asks "are you on other medications?" A real visit asks "when do you take them and have you noticed anything?"
4. Mental health context is missed. GLP-1s have been associated with mood changes in a subset of patients. An async form isn't going to notice someone is in distress.
5. Titration guidance is templated. When you message your platform in week 6 with side effects, an async-only operation often responds with a canned "increase fluids and rest." A synchronous platform gets you a 15-minute check-in.

How to tell which kind you're on

Look at three things:

• The sign-up flow. If the longest "visit" is a 10-minute text questionnaire, you're on async.
• The "contact your provider" button. If your only channel to the clinician is a chat thread that replies in 24–72 hours, async.
• The refill cadence. If refills renew automatically with no check-in, async.

Synchronous platforms in the GLP-1 space typically cost more ($60–120 more per month) and take longer to onboard (7–10 days instead of 24 hours). You're paying for clinician time, and you usually feel the difference by month three.

The "hybrid" model — and why it's the smart middle path

A small but growing number of platforms (MEDVi, Sesame Care, Sequence/Weight Watchers Clinic) run a hybrid: async for the intake screening, synchronous for anything clinically interesting (eligibility edge cases, side effects, dose changes). This is probably the right model for most patients and is what we'd expect to become standard as the FDA tightens compounded-GLP-1 rules.

When async is the right call

We're not anti-async. For the right patient, it's genuinely the most efficient way to get ongoing care that was otherwise inaccessible or unaffordable. Good async candidates:

• Have a current, recent visit with a primary care physician who knows their health history.
• Have current labs (metabolic panel, HbA1c) within the last 12 months.
• Are on few or no other medications.
• Have straightforward eligibility — BMI clearly qualifying, no cancer history, no pancreatitis, no pregnancy.
• Have a realistic understanding of side effects and a plan for them.

If that's you, async is fine. If it's not — if you're juggling medications, if you have cardiac or thyroid history, if you're not sure whether you actually qualify — the extra $60 a month for a synchronous visit is the best healthcare value on the market.

The question to ask any platform

Before signing up, email support one sentence: "Before you prescribe, will a clinician speak with me on video or phone?"

The answer tells you which kind of company you're about to hand your credit card to. It also tells you whether they'll respond to a real question in the first place — which is its own useful data point.